The Ministry of Health of the Perm Region and Medisorb JSC have signed the region’s first-ever offset contract. The agreement stipulates an investment of at least 100 million rubles in production modernization in exchange for guaranteed product off-take for regional healthcare needs over a 10-year period.
Economics and Contract Terms
Under the terms of the contract, the pharmaceutical enterprise is required to implement a technological upgrade of its facilities within the Perm Region during the first four years. In return, the region commits to purchasing pharmaceutical products for a total amount of 438 million rubles. The offset contract mechanism allows authorities not only to attract investment into the real sector but also to fix the prices of vital medicines for a long-term period.
“For the first time in the history of Perm healthcare, we have managed to conclude an offset contract, which allowed us to fix the cost of medications for the next 10 years and will also support our import substitution goals.”
— Anastasia Kruten, Minister of Health of the Perm Region
Product Range and Import Substitution
Within the framework of the project, the production of 18 INNs (International Nonproprietary Names) from the Vital and Essential Drugs (VED) list will be localized. The output will cover regional needs in critical therapeutic areas such as cardiology, endocrinology, and hematology. The bulk of the supplies (over 18 million packs) will consist of modern therapies for diabetes mellitus.
| Key Parameters | Value |
|---|---|
| Private Investment Volume | min. 100M RUB |
| Guaranteed Purchase Amount | 438M RUB |
| Contract Duration | 10 years |
| Start of Supplies | 2026 |
For Medisorb, this contract is a core component of its strategy for import substitution and generic portfolio expansion, which was further bolstered by the 2025 acquisition of the Moscow-based Kinetic-pharm laboratory. For more details, visit the manufacturer’s official website.
